核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展  

Nucleotide excision repair genetic polymorphisms and resistance of platinum

作　　者：陈健[1] 何义富[1] 胡冰[1] 

机构地区：[1]安徽医科大学附属安徽省立医院肿瘤内科,安徽合肥230001

出　　处：《现代肿瘤医学》2009年第4期763-766,共4页Journal of Modern Oncology

基　　金：安徽省自然科学基金项目(070413256X)

摘　　要：铂类药物广泛用于实体肿瘤的化疗,其作用机制与肿瘤细胞DNA的损伤有关,然而,机体的DNA修复机制可以将这些损伤修复。核苷酸切除修复是DNA修复中的一种,目前认为核苷酸切除修复与铂类药物的耐药相关。本文就核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展作一综述。Platinating agents are some of the most widely used anti - cancer drugs in solid tumors. The cytotoxicity of them is directly related to their ability to cause DNA intra - strand crosslinks, which are processed and repaired by the nucleotide excision repair pathway. It is now clear that nucleotide excision repair （NER） capacity may have a major impact on the emergence of resistance and patient outcomes. In this review ,we provide an overview of human NER genetic polymorphisms as a predictive and prognostic marker in cancer.

关 键 词：化疗 核苷酸切除修复 基因多态性 铂类药物 耐药 

分 类 号：R730.23[医药卫生—肿瘤] R730.53[医药卫生—临床医学]